rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121913279
|
|
|
0.740 |
GeneticVariation |
BEFREE |
All mutations were mutually exclusive, apart from one basal-like breast tumour which harboured mutations in both MET (p.T992I) and PIK3CA (p.H1047R).
|
24318467 |
2014 |
rs121913279
|
|
|
0.740 |
GeneticVariation |
BEFREE |
We found that activation of the latent Pik3ca(H1047R) allele resulted in breast tumors with multiple histological types.
|
22370636 |
2013 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
|
21558396 |
2011 |
rs121913279
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Our results suggest that the PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R.
|
21482677 |
2011 |
rs121913279
|
|
|
0.740 |
GeneticVariation |
BEFREE |
In addition, the combined treatment of DSF and LY294002 significantly inhibited the growth of the breast tumor xenograft in nude mice induced by MDA-MB-231 cells expressing mutant PIK3CA-H1047R and PIK3CA-E545K, whereas neither DSF nor LY294002 alone could significantly retard tumor growth.
|
20424113 |
2010 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
18676830 |
2008 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
18676830 |
2008 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
|
15805248 |
2005 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
|
15805248 |
2005 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
|
15647370 |
2005 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
|
15647370 |
2005 |
rs121913279
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
The PIK3CA gene is mutated with high frequency in human breast cancers.
|
15254419 |
2004 |
rs121913279
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
The PIK3CA gene is mutated with high frequency in human breast cancers.
|
15254419 |
2004 |
rs104894230
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Application of these signatures to breast tumor gene expression data identified two novel discrete phenotypes characterized by concordant, aberrant activation of either the HER2, IGF1R, and AKT pathways ("the survival phenotype") or the EGFR, KRAS (G12V), RAF1, and BAD pathways ("the growth phenotype").
|
28446242 |
2017 |
rs876660754
|
|
|
0.710 |
GeneticVariation |
BEFREE |
A direct sequencing analysis of p53 revealed a p.V173M mutation in exon 5 in both the breast tumor and the ovarian cancer.
|
28662703 |
2017 |